GlassScriptPhysician profile
Kevin Bauerle
NPI 1861757346
$1,716.88
in general payments reported to CMS, 2019-2025
21 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $421 · 2021: $283 · 2023: $16.15 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $412.76 | 2019-2021 | |
| Medtronic Minimed, INC. | $391.08 | 2019-2020 | |
| Amgen INC. | $140.02 | 2019-2025 | Tepezza |
| Novo Nordisk INC | $128.50 | 2019-2025 | Wegovy |
| Dexcom, INC. | $91.64 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $79.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $71.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $58.12 | 2019-2020 | |
| Lilly USA, LLC | $48.11 | 2019 | |
| Corcept Therapeutics | $38.68 | 2019-2020 | |
| Insulet Corporation | $37.76 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.71 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.38 | 2019 | |
| Madrigal Pharmaceuticals | $26.54 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $21.91 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $19.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2021 | |
| Ascendis Pharma Endocrinology INC | $16.15 | 2023 | |
| Amarin Pharma, INC. | $14.69 | 2019 | |
| Amryt Pharma Holdings LTD | $13.18 | 2020 | |
| Tandem Diabetes Care, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bauerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.